1Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin In fect Dis, 2003,36 : 687-696.
2WHO (World Health Organization). Fact Sheet 204. Accessed December 19, 2006.
4Lok AS, Lai CL, Leung N, et al. Longterm safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125: 1714- 1722.
5Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology, 2001, 33(3): 751.
6Ayres A, Bartholomeusz A, Lau G, et al. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol, 2003, 27(1) : 111.
7YatsujiH, NoguchiC, HiragaN, et al, Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents CH, 2006, 50 ( 11 ) : 3867-3874.
8Warner N, Locarnini S, Kuiper I, et al. The L801 substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents CH, 2007, 51(7) : 2285- 92.
9Fung SK, Lok AS. Drug insight: nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol, 2004, 1(2): 90-97.
10Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37:256 -265.
10Zollner B, Petersen J, Schroter M, et al. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet, 2001,357: 934-935.
